Další formáty:
BibTeX
LaTeX
RIS
@misc{2361057, author = {Brzoňová, Jana}, address = {Praha}, edition = {NA}, keywords = {CART19; anti-CD19; chimeric antigen receptor; Acute Lymphoblastic Leukemia;Non-Hodgkin Lymphoma}, language = {eng}, location = {Praha}, publisher = {ÚHKT PRAHA}, title = {Zpráva č.3 o průběhu klinického hodnocení CART19 9.6.2022 — 8.6.2023}, url = {https://test.uhkt.cz/clinical-trials/clinical-trials}, year = {2023} }
TY - GEN ID - 2361057 AU - Brzoňová, Jana PY - 2023 TI - Zpráva č.3 o průběhu klinického hodnocení CART19 9.6.2022 — 8.6.2023 VL - NA PB - ÚHKT PRAHA CY - Praha KW - CART19 KW - anti-CD19 KW - chimeric antigen receptor KW - Acute Lymphoblastic Leukemia;Non-Hodgkin Lymphoma UR - https://test.uhkt.cz/clinical-trials/clinical-trials N2 - Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. EudraCT 2018-004789-32, ÚHKT-CAR19-01, NCT05054257: Safety and efficacy of anti-CD19 chimeric antigen receptor-modified autologous T cells (CART19) in patients with relapsed/refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin Lymphoma. A dose escalation, open-Iabel, phase I study. (Principal Investigator: MUDr. Jan Vydra, Ph.D., ER -
BRZOŇOVÁ, Jana. \textit{Zpráva č.3 o průběhu klinického hodnocení CART19 9.6.2022 — 8.6.2023}. NA. Praha: ÚHKT PRAHA, 2023, 4 s. NA.
|